Oncology

Based on these findings, the investigators encourage further research into this promising combination.

Asian women with breast cancer receiving chemotherapy had the highest persistent chemotherapy-induced alopecia (PCIA) incidence and alopecia-related distress vs their White, Black, and Hispanic or Latino peers.

Reader favorites from the 2025 Patient-Centered Oncology Care conference included articles and interviews featuring AI's role in precision medicine and the importance of collaboration in delivering care.

From home-based monitoring and subcutaneous immunotherapy to expanded community cancer networks, 2025 marked a pivotal year in rethinking how cancer care is delivered.

A recent review suggests women with ovarian or colorectal cancer face a higher risk of developing the other, highlighting the need for surveillance.

The foundation of medically integrated pharmacy includes 7 critical pillars. This commentary focuses on the benefits of 3 of those pillars: abandonment, adherence, and access/affordability.

Linvoseltamab shows promise as a first-line therapy for multiple myeloma, offering high response rates and a simplified treatment approach.

Eunice Wang, MD, highlights breakthroughs in menin inhibitors for acute leukemias, showcasing promising combination therapies and addressing treatment challenges at ASH 2025.

Five key oncology FDA approvals came through last month, expanding treatment options across multiple cancer types.

This approval makes durvalumab with FLOT chemotherapy the first perioperative immunotherapy for resectable gastric or gastroesophageal junction adenocarcinoma.

The FDA approved selumetinib for adults with neurofibromatosis type 1 and symptomatic, inoperable plexiform neurofibromas based on the KOMET trial.

Only about 2% of cases of rhabdomyosarcoma primarily arise from the chest wall, and such cases require careful planning.

Global ovarian and uterine cancer cases due to high BMI have risen sharply over the past 30 years, especially in low- to middle-income sociodemoraphic regions.

Speakers at AMCP Nexus 2025 reviewed the oncology pipeline, highlighting expanded indications and new therapies advancing innovation, access, and value.

New reporting suggests obesity and diffuse large B-cell lymphoma (DLBCL) have shared genetic risk factors.

Treatment options for patients with small cell lung cancer (SCLC) who survive to a third line of therapy are insufficient, authors of a new study argue.

Payer contracts should incentivize the delivery of comprehensive, total-person cancer care, says Brian Mulherin, MD.

Many cancer survivors face ongoing physical and mental health challenges, which peer support and online resources can help address, says Brian Koffman, MDCM, DCFP, FCFP, DABFP, MSEd.

Despite systemic challenges, oncology practices use value-based care, community partnerships, and clinical trials to improve patient access and outcomes, says Brian Mulherin, MD.

Vivek Subbiah, MD, says artificial intelligence (AI) should assist clinicians in precision oncology, not replace human decision-making.

Artificial intelligence, automation, and expanded pharmacist roles help reduce administrative burdens, improve workflow, and support providers in delivering cancer care, according to Scott Soefje, PharmD, MBA, BCOP.

Early research has identified several antigens that could help facilitate the use of chimeric antigen receptor T cells in small cell lung cancer.

Emotional well-being and social engagement significantly impact quality of life for patients with soft tissue sarcoma post-surgery.

Scott Soefje, PharmD, MBA, BCOP, discusses how remote patient monitoring and caregiver support enable safe outpatient delivery of bispecific antibodies and antibody-drug conjugates.

Stronger partnerships between primary care and oncology improve patient outcomes by ensuring coordinated care and addressing financial and systemic barriers, says Mark Fendrick, MD.